SillaJen Inc (215600) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.040x

Based on the latest financial reports, SillaJen Inc (215600) has a cash flow conversion efficiency ratio of -0.040x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-4.74 Billion ≈ $-3.21 Million USD) by net assets (₩117.80 Billion ≈ $79.83 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of SillaJen Inc to measure how many days the company can operate on defensive assets alone.

SillaJen Inc - Cash Flow Conversion Efficiency Trend (2015–2024)

This chart illustrates how SillaJen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.

SillaJen Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of SillaJen Inc ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Tiansheng Pharmaceutical Group Co Ltd
SHE:002872
-0.011x
Rane (Madras) Limited
NSE:RML
0.032x
Arkade Developers Ltd
NSE:ARKADE
-0.049x
Shenzhen Wongtee International Enterprise Co Ltd
SHE:000056
-0.028x
Shandong Kehui Power Automation Co Ltd
SHG:688681
0.036x
Squirrel Media SA
MC:SQRL
0.076x
Samsung Sdi Co Pref
KO:006405
0.023x
ACELYRIN, INC. Common Stock
NASDAQ:SLRN
-0.096x

Annual Cash Flow Conversion Efficiency for SillaJen Inc (2015–2024)

The table below shows the annual cash flow conversion efficiency of SillaJen Inc from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see SillaJen Inc market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 ₩131.82 Billion
≈ $89.33 Million
₩-17.83 Billion
≈ $-12.08 Million
-0.135x +54.44%
2023-12-31 ₩57.31 Billion
≈ $38.84 Million
₩-17.02 Billion
≈ $-11.53 Million
-0.297x -5.86%
2022-12-31 ₩78.94 Billion
≈ $53.50 Million
₩-22.14 Billion
≈ $-15.00 Million
-0.280x +50.07%
2021-12-31 ₩108.05 Billion
≈ $73.22 Million
₩-60.69 Billion
≈ $-41.13 Million
-0.562x +43.98%
2020-12-31 ₩22.88 Billion
≈ $15.51 Million
₩-22.94 Billion
≈ $-15.55 Million
-1.003x -241.83%
2018-12-31 ₩165.09 Billion
≈ $111.88 Million
₩-48.43 Billion
≈ $-32.82 Million
-0.293x -275.11%
2017-12-31 ₩201.95 Billion
≈ $136.86 Million
₩33.83 Billion
≈ $22.93 Million
0.168x +117.60%
2016-12-31 ₩207.97 Billion
≈ $140.94 Million
₩-197.98 Billion
≈ $-134.17 Million
-0.952x -269.66%
2015-12-31 ₩86.94 Billion
≈ $58.91 Million
₩-22.39 Billion
≈ $-15.17 Million
-0.258x --

About SillaJen Inc

KQ:215600 Korea Biotechnology
Market Cap
$229.34 Million
₩338.42 Billion KRW
Market Cap Rank
#16098 Global
#575 in Korea
Share Price
₩2450.00
Change (1 day)
-5.04%
52-Week Range
₩2420.00 - ₩4975.00
All Time High
₩121250.15
About

SillaJen, Inc. engages in developing technologies and products using genetic engineering in South Korea. The company develops Pexa-Vec, which is in phase 2 clinical trial to treat renal Cell Carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. It also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-6… Read more